[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Travere Therapeutics Inc (TVTX)

Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,857,379
  • Shares Outstanding, K 94,261
  • Annual Sales, $ 490,730 K
  • Annual Income, $ -25,550 K
  • EBIT $ -40 M
  • EBITDA $ 17 M
  • 60-Month Beta 1.12
  • Price/Sales 11.80
  • Price/Cash Flow 169.63
  • Price/Book 236.13

Options Overview Details

View History
  • Implied Volatility 43.90% (+0.11%)
  • Historical Volatility 42.31%
  • IV Percentile 2%
  • IV Rank 2.05%
  • IV High 220.62% on 03/19/26
  • IV Low 40.19% on 05/05/26
  • Expected Move (DTE 4) 2.47 (3.89%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 60
  • Volume Avg (30-Day) 480
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 34,745
  • Open Int (30-Day) 31,972
  • Expected Range 60.97 to 65.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.03
  • Number of Estimates 4
  • High Estimate $0.32
  • Low Estimate $-0.17
  • Prior Year $0.28
  • Growth Rate Est. (year over year) -89.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.42 +19.08%
on 08/03/26
66.24 -3.96%
on 08/05/26
+6.91 (+12.18%)
since 07/17/26
3-Month
41.32 +53.96%
on 05/19/26
66.24 -3.96%
on 08/05/26
+21.03 (+49.37%)
since 05/15/26
52-Week
17.05 +273.11%
on 08/27/25
66.24 -3.96%
on 08/05/26
+44.80 (+238.02%)
since 08/15/25

Most Recent Stories

More News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting...

TVTX : 64.28 (+3.44%)
Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity's 46th...

TVTX : 64.28 (+3.44%)
Travere: Q2 Earnings Snapshot

Travere: Q2 Earnings Snapshot

TVTX : 64.28 (+3.44%)
Travere Therapeutics Reports Second Quarter 2026 Financial Results

Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during the second quarter U.S. net product sales of FILSPARI grew 96%...

TVTX : 64.28 (+3.44%)
Travere Therapeutics to Report Second Quarter 2026 Financial Results

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company will...

TVTX : 64.28 (+3.44%)
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

NEW YORK , July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ:...

TVTX : 64.28 (+3.44%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares...

TVTX : 64.28 (+3.44%)
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

TVTX : 64.28 (+3.44%)
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

William Rote, Ph.D., chief research officer plans to retire in early 2027 Jula Inrig, M.D., to be named executive vice president, head of research and development and...

TVTX : 64.28 (+3.44%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of...

TVTX : 64.28 (+3.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 64.93
2nd Resistance Point 63.71
1st Resistance Point 62.92
Last Price 64.28
1st Support Level 60.91
2nd Support Level 59.69
3rd Support Level 58.90

See More

52-Week High 66.24
Last Price 64.28
Fibonacci 61.8% 47.45
Fibonacci 50% 41.64
Fibonacci 38.2% 35.84
52-Week Low 17.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.